Digital quantification of mutant DNA in cancer patients

Current Opinion in Oncology

Volumn 19, Issue 1, 2007, Pages 36-42

  Diehl, Frank ^a,b   Diaz Jr , Luis A ^a  

^a Ludwig Center for Cancer Genetics and Therapeutics   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarker; Molecular diagnostics; Mutation; Quantification; Single molecule detection

Indexed keywords

DNA;

CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIGITAL COMPUTER; GENE AMPLIFICATION; GENE LOCUS; GENETIC SCREENING; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; TUMOR CELL;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 33845351497     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328011a8e7     Document Type: Review

References (52)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-799.
2. Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11:199-208.
3. Strom CM. Mutation detection, interpretation, and applications in the clinical laboratory setting. Mutat Res 2005; 573 (1-2):160-167. This review highlights the role of quantitative assays in diagnostic testing.
4. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006 [Epub ahead of print].
5. Foy CA, Parkes HC. Emerging homogeneous DNA-based technologies in the clinical laboratory. Clin Chem 2001; 47:990-1000.
6. Whitcombe D, Newton CR, Little S. Advances in approaches to DNA-based diagnostics. Curr Opin Biotechnol 1998; 9:602-608.
7. Mike Makrigiorgos G. PCR-based detection of minority point mutations. Hum Mutat 2004; 23:406-412.
8. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005; 7:413-421.
9. Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12 (3 Pt 1):751-758.
10. Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004; 1:141-147.
11. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with nonsmall-cell lung cancer. Clin Cancer Res 2006; 12:3915-3921. Report on a blood-based assay to detect EGFR mutations in lung cancer. They used a Scorpion Amplified Refractory Mutation System for mutation detection.
12. Pohl G, Shih Ie M. Principle and applications of digital PCR. Expert Rev Mol Diagn 2004; 4:41-47.
13. Kraytsberg Y, Khrapko K. Single-molecule PCR: an artifact-free PCR approach for the analysis of somatic mutations. Expert Rev Mol Diagn 2005; 5:809-815. Recent review about digital PCR approaches for the analysis of somatic mutations.
14. Castro A, Williams JG. Single-molecule detection of specific nucleic acid sequences in unamplified genomic DNA. Anal Chem 1997; 69:3915-3920.
15. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102:16368-16373. Application of BEAMing for the quantification of mutant DNA in plasma from cancer patients.
16. Lizardi PM, Huang X, Zhu Z, et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet 1998; 19:225-232.
17. Nie B, Shortreed MR, Smith LM. Scoring single-nucleotide polymorphisms at the single-molecule level by counting individual DNA cleavage events on surfaces. Anal Chem 2005; 77:6594-6600.
18. Jarvius J, Melin J, Goransson J, et al. Digital quantification using amplified single-molecule detection. Nat Methods 2006; 3:725-727. First report describing the counting of RCA products in solution.
19. Bielas JH, Loeb LA. Quantification of random genomic mutations. Nat Methods 2005; 2:285-290. Sensitive assay for measuring the background mutation rate in human cells.
20. Weiss S. Fluorescence spectroscopy of single biomolecules. Science 1999; 283:1676-1683.
21. Yeh HC, Chao SY, Ho YP, et al. Single-molecule detection and probe strategies for rapid and ultrasensitive genomic detection. Curr Pharm Biotechnol 2005; 6:453-461. Review of state-of-the-art single-molecule detection methods.
22. Wabuyele MB, Farquar H, Stryjewski W, et al. Approaching real-time molecular diagnostics: single-pair fluorescence resonance energy transfer (spFRET) detection for the analysis of low abundant point mutations in K-ras oncogenes. J Am Chem Soc 2003; 125:6937-6945.
23. Nie B, Shortreed MR, Smith LM. Quantitative detection of individual cleaved DNA molecules on surfaces using gold nanoparticles and scanning electron microscope imaging. Anal Chem 2006; 78:1528-1534. Method for counting of mutant DNA molecules bound to a solid support.
24. Shendure J, Mitra RD, Varma C, et al. Advanced sequencing technologies: methods and goals. Nat Rev Genet 2004; 5:335-344.
25. Bennett ST, Barnes C, Cox A, et al. Toward the 1,000 dollars human genome. Pharmacogenomics 2005; 6:373-382.
26. Metzker ML. Emerging technologies in DNA sequencing. Genome Res 2005; 15:1767-1776.
27. Braslavsky I, Hebert B, Kartalov E, et al. Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci USA 2003; 100:3960-3964.
28. Jeffreys AJ, Wilson V, Neumann R, et al. Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. Nucleic Acids Res 1988; 16:10953-10971.
29. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999; 96:9236-9241.
30. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858-865.
31. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95:484-486.
32. Shih IM, Yan H, Speyrer D, et al. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. Am J Surg Pathol 2001; 25:1095-1099.
33. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-320.
34. Traverso G, Diehl F, Hurst R, et al. Multicolor in vitro translation. Nat Biotechnol 2003; 21:1093-1097.
35. Mitra RD, Church GM. In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res 1999; 27:e34.
36. Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003; 100:8817-8822.
37. Leamon JH, Lee WL, Tartaro KR, et al. A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis 2003; 24:3769-3777.
38. Li M, Diehl F, Dressman D, et al. BEAMing up for detection and quantification of rare sequence variants. Nat Methods 2006; 3:95-97. Approach to increase the DNA copy number on beads generated by BEAMing.
39. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437:376-380. Application of a new highly parallel sequencing system for the resequencing of the mycoplasma genome.
40. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006; 12:852-855. Application of 454 sequencer for the detection and quantification of EGFR mutations in lung cancer biopsies.
41. Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005; 309:1728-1732. Application of new beads-based sequencing technology for the resequencing of Escherichia coli.
42. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:66-70.
43. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006; 24:3299-3308.
44. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2:210-219.
45. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5:845-856. Review about advances in biomarker development.
46. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-2653.
47. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37.
48. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461-2470.
49. Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol 2005; 23:1623-1626.
50. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006; 18:48-56.
51. Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 2006; 84:365-377. Review about the quantification of methylated DNA in cancer patients.
52. Goebel G, Zitt M, Zitt M, et al. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 2005; 21:105-120. Review about the value of detecting mutant DNA in the circulation of cancer patients.